There are currently no known outstanding effects for the The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020, Paragraph 64.
64. In regulation 87 (post authorisation requirements in relation to UK marketing authorisations with paediatric aspects and advanced therapy medicinal products), in the inserted regulation 78B (post authorisation requirements in relation to UK marketing authorisations for advanced therapy medicinal products)—U.K.
(a)in the heading to the regulation for “UK marketing authorisations” substitute “ UKMA(GB) ”;
(b)for “UK marketing authorisation” in each place it appears substitute “ UKMA(GB) ”.
Commencement Information
I1Sch. 2 para. 64 in force at 31.12.2020 immediately before IP completion day, see reg. 1
All content is available under the Open Government Licence v3.0 except where otherwise stated. This site additionally contains content derived from EUR-Lex, reused under the terms of the Commission Decision 2011/833/EU on the reuse of documents from the EU institutions. For more information see the EUR-Lex public statement on re-use.
